ABSTRACT
INTRODUCTION

I
n Pharmacopeial Forum 33(3) USP authors published a Stimuli article titled "Proposed Change to Acceptance Criteria for Dissolution Performance Verification Testing" (1) . This article elicited a number of comments, which are published here with USP responses. Comments have been edited for publication.
Respondent 1 1. The fundamental proposal made by USP for the revised acceptance criteria is to test more tablets to overcome tablet variability. It is apparent that there is an issue with the quality of the USP Reference Standard (RS) Tablets. Based on the results of queries to our relevant departments, we have several reports of examples that demonstrate the poor quality of USP RS Tablets.
USP disagrees with these statements based on data (2, 3). The first reference (2) provides results from subjecting USP Lot P Prednisone RS tablets to the tests, procedures, and acceptance criteria that might be used for a commercial tablet. The data indicate results that are not dissimilar to those required in many USP monographs for drug products legally marketed in the US. The second reference (3) provides an analysis indicating that the contribution of the Prednisone RS Tablet to Performance Verification Test (PVT) variability is low (<4%-5% USP regrets this situation. USP hopes to advance a concomitant PVT for all apparatus and for all USP performance tests for dosage forms given by any of the five routes of administration (10) (11) (12) (13) . USP scientists recently published results of their work on a PVT for the vertical diffusion cell (Franz cell) (14) . The applied compendial research needed to support the development of a PVT for all apparatus is resource intensive and would proceed faster if there were a combined and sustained government, industry, and compendial effort. The goal of consistently performing dosage form testing within and between manufacturers would seem to be a logical goal of efforts now termed Quality by Design.
Because the PVT includes analyst and equipment, the use of designated service personnel or external vendors causes the PVT to lose all value.
The respondent is correct that a PVT comprises an assessment of analyst and analytical procedure as well as dissolution apparatus and assembly. USP agrees that a laboratory may lose to its detriment some of the value of the PVT when the latter is conducted by personnel other than the laboratory's regular analysts. For this reason USP recommends that the PVT be performed using the regular laboratory personnel and, regardless who conducts the PVT, that the laboratory's standard procedures be followed. USP does not agree that use of designated service personnel or external vendors causes a PVT to lose all value. The PVT remains an assessment of the assembly, its operating environment, and laboratory procedure. Also, PVT would seem to be a useful way to monitor performance of such designated personnel or external vendors. In addition to the formal PVT itself the USP PVT RS and their externally derived acceptance criteria can be used as a proficiency test as part of training for laboratory personnel. This comment speaks to a frequently heard theme that one of the supplied Reference Materials for the PVT, Prednisone RS Tablets, does not have good quality and is the source of failure in laboratories conducting the PVT. This theme is addressed in the USP response to Respondent 1 and references therein. The respondent is correct that the change in acceptance criteria, which occurred on 31 July 2007, signals a change in the performance of the USP Lot P Prednisone RS Tablet. USP is working diligently to correct this, although USP does not believe that the change negates the value of the tablet's use in the PVT. The task of making a Reference Material that releases at a slow rate (a rapidly releasing Reference Material would be of no value in a dissolution PVT) and that also has requisite sensitivity to factors not readily assessed by mechanical calibration is a challenging one. USP has prepared a public response in this matter available at http://www.usp.org/USPNF/notices/ prednisoneTabletsErrata.html, accessed 25 October 2007.
Respondent 3 1. USP mentioned the power of increasing from 6 to 12 to 18 tablets, but the authors did not provide any power curves or calculations. Are these power calculations available or perhaps contained in one of the references?
The power results are not currently available. The authors will prepare a summary report for the Biopharmaceutics Expert Committee, and, based on this comment, they intend to make the requested information publicly available. No decision has been made as yet about what form this will take.
As another option, wouldn't a two-stage sampling plan be worth investigating?
The two-stage suggestion is a good one and will be included in the report as well. The congruence with other dissolution criteria makes it very appealing.
Respondent 4
General comment: Rejecting the ISO approach, the respondent calls for focus on performance of an individual apparatus, which is more stringent than a "combined test" that takes into account "Reference Material, medium de-aeration, analyst, laboratory, and the apparatus."
USP response: This idea has merit, and USP will further consider it. 
Suitability of Apparatus 1 for disintegrating tablets:
This should be phased out because disintegrated tablet particles fall through the basket screen, and results depend on how many and how soon particles fall through the screen. USP believes this comment has merit and will consider it further.
Respondent 5 1. Quality of the RS Tablet.
See USP's response to Respondent 1 and references therein.
Setting of acceptance criteria from collaborative data:
Learning from collaborative studies of USP Lot P RS to set more appropriate specification ranges. USP agrees with this comment. The acceptance criteria for any performance standard material will need to be established by analysis of collaborative testing. The collaborative study for Prednisone RS Tablets Lot P was instructive in many ways, and USP expects it to be helpful in planning further collaborative studies (2-7).
Keeping both RS Tablets and adopting the proposals
would double the testing. This will be a huge burden on the industry. USP agrees with this comment, and a specific vote of the Biopharmaceutics Expert Committee recommended phasing out the Salicylic Acid RS Tablets at the appropriate time.
